2022 / 05

Next Paper
DOI: 10.24075/brsmu.2022.048
Copyright: © 2022 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Antiphospholipid antibodies and outcomes of assisted reproductive technology programs in patients with a history of COVID-19

Ermakova DM, Dolgushina NV, Menzhinskaya IV, Lomova NA, Vtorushina VV
About authors

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia

Correspondence should be addressed: Irina V. Menzhinskaya
Akademika Oparina, 4, Moscow, 117997, Russia; ur.4anirapo@ayaksniznem_i

About paper

Funding: the work was supported by the Vklad v buduscheye (Investment in the Future) charity foundation as part of the Stop Coronavirus Together program-campaign.

Author contribution: Ermakova DM, Lomova NA — management of patients participating in the study, article authoring; Dolgushina NV — collection and analysis of literature data, manuscript editing, statistical data analysis; Menzhinskaya IV — execution of the laboratory part of the study, article authoring and editing; Vtorushina VV — execution of the laboratory part of the study

Compliance with ethical standards: the study was approved by the Ethics Committee of Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology (Minutes of meeting № 12 of November 26, 2020); all patients signed an informed voluntary consent to participation in the study.

Received: 2022-09-07 Accepted: 2022-09-30 Published online: 2022-10-31
|
Table 1. Serum aPL level growth incidence in the study groups
Note: abs (%), χ2 test; * — comparison of groups 1 and 2; ** — comparison of group 1 and subgroups 2a and 2b.
Table 2. The average level of blood serum aPL, both study groups
Note: Mе (Q25–Q75), тест Манна–Уитни или Краскела–Уоллиса; * — при сравнении групп 1 и 2, ** — при сравнении группы 1 и подгрупп 2а и 2б.